{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:39:50Z","timestamp":1792132790926,"version":"4.4.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019035","name":"Science and Technology Program of Hubei Province","doi-asserted-by":"publisher","award":["2022BCA018"],"award-info":[{"award-number":["2022BCA018"]}],"id":[{"id":"10.13039\/501100019035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Corona Virus Disease 2019 (COVID-19) continues to be a burden for human health since its outbreak in Wuhan, China in December 2019. Recently, the emergence of new variants of concerns (VOCs) is challenging for vaccines and drugs efficiency. In severe cases, SARS-CoV-2 provokes inappropriate hyperinflammatory immune responses leading to acute respiratory distress syndrome (ARDS) and even death. This process is regulated by inflammasomes which are activated after binding of the viral spike (S) protein to cellular angiotensin-converting enzyme 2 (ACE2) receptor and triggers innate immune responses. Therefore, the formation of \u201ccytokines storm\u201d leads to tissue damage and organ failure. NOD-like receptor family pyrin domain containing 3 (NLRP3) is the best studied inflammasome known to be activated during SARS-CoV-2 infection. However, some studies suggest that SARS-CoV-2 infection is associated with other inflammasomes as well; such as NLRP1, absent in melanoma-2 (AIM-2), caspase-4 and -8 which were mostly found during dsRNA virus or bacteria infection. Multiple inflammasome inhibitors that exist for other non-infectious diseases have the potential to be used to treat severe SARS-CoV-2 complications. Some of them have showed quite encouraging results during pre- and clinical trials. Nevertheless, further studies are in need for the understanding and targeting of SARS-Cov-2-induced inflammasomes; mostly an update of its role during the new VOCs infection is necessary. Hence, this review highlights all reported inflammasomes involved in SARS-CoV-2 infection and their potential inhibitors including NLRP3- and Gasdermin D (GSDMD)-inhibitors. Further strategies such as immunomodulators and siRNA are also discussed. As highly related to COVID-19 severe cases, developing inflammasome inhibitors holds a promise to treat severe COVID-19 syndrome effectively and reduce mortality.<\/jats:p>","DOI":"10.3389\/fcimb.2023.1218039","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T05:09:56Z","timestamp":1686287396000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Inflammasomes during SARS-CoV-2 infection and development of their corresponding inhibitors"],"prefix":"10.3389","volume":"13","author":[{"given":"Rominah Onintsoa","family":"Diarimalala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanghong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.147610","article-title":"Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury","volume":"6","author":"Andargie","year":"2021","journal-title":"JCI Insight"},{"key":"B2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.7150\/ijbs.47827","article-title":"SARS-CoV-2 variants evolved during the early stage of the pandemic and effects of mutations on adaptation in wuhan populations","volume":"17","author":"Awadasseid","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0811","article-title":"Human NLRP1 is a sensor for double-stranded RNA","volume":"371","author":"Bauernfried","year":"2021","journal-title":"Sci. (New York N.Y.)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.apsb.2021.02.006","article-title":"Gasdermin d in pyroptosis","volume":"11","author":"Burdette","year":"2021","journal-title":"Acta Pharm. Sinica. B"},{"key":"B5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102295","article-title":"SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway","volume":"24","author":"Campbell","year":"2021","journal-title":"iScience"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1080\/21655979.2022.2031417","article-title":"COVID-19 in southeast Asia: current status and perspectives","volume":"13","author":"Chu","year":"2022","journal-title":"Bioengineered"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.934264","article-title":"Activation of the AIM2 receptor in circulating cells of post-COVID-19 patients with signs of lung fibrosis is associated with the release of IL-1\u03b1, IFN-\u03b1 and TGF-\u03b2","volume":"13","author":"Colarusso","year":"2022","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155934","article-title":"Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection: from prognostic marker to therapeutic agent","volume":"157","author":"Declercq","year":"2022","journal-title":"Cytokine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202012119","article-title":"Caspase-4\/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and immunothrombosis","volume":"119","author":"Eltobgy","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B11","doi-asserted-by":"publisher","first-page":"15874","DOI":"10.1021\/acsnano.1c03726","article-title":"Treating autoimmune inflammatory diseases with an siERN1-nanoprodrug that mediates macrophage polarization and blocks toll-like receptor signaling","volume":"15","author":"Feng","year":"2021","journal-title":"ACS nano"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259061","article-title":"Disulfiram use is associated with lower risk of COVID-19: a retrospective cohort study","volume":"16","author":"Fillmore","year":"2021","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013652.pub2","article-title":"Antibody tests for identification of current and past infection with SARS-CoV-2","volume":"11","author":"Fox","year":"2022","journal-title":"Cochrane Database systematic Rev."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01518","article-title":"Targeting the NLRP3 inflammasome in severe COVID-19","volume":"11","author":"Freeman","year":"2020","journal-title":"Front. Immunol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah4066","article-title":"Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice","volume":"10","author":"Gordon","year":"2018","journal-title":"Sci. Trans. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1186\/s13054-020-03312-8","article-title":"Anakinra: a silver lining in COVID-19","volume":"24","author":"Gupta","year":"2020","journal-title":"Crit. Care (London England)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2313","article-title":"Covid-19 vaccines and variants of concern: a review","volume":"32","author":"Hadj Hassine","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/path.2067","article-title":"Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS","volume":"210","author":"He","year":"2006","journal-title":"J. Pathol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat. Commun."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet (London England)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.ymthe.2021.05.004","article-title":"A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19","volume":"29","author":"Idris","year":"2021","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J. Exp. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"rs.3.rs","DOI":"10.21203\/rs.3.rs-153628\/v1","article-title":"SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release","author":"Junqueira","year":"2021","journal-title":"Res. Square"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.3390\/v13122513","article-title":"Inflammasomes and SARS-CoV-2 infection","volume":"13","author":"Kaivola","year":"2021","journal-title":"Viruses"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e586","DOI":"10.1016\/s2665-9913(20)30273-3","article-title":"Anakinra for severe forms of COVID-19","volume":"2","author":"Khan","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","article-title":"The architecture of SARS-CoV-2 transcriptome","volume":"181","author":"Kim","year":"2020","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.12688\/f1000research.22211.2","article-title":"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in wuhan, China","volume":"9","author":"Kruse","year":"2020","journal-title":"F1000Research"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/jmv.27526","article-title":"Omicron and delta variant of SARS-CoV-2: a comparative computational study of spike protein","volume":"94","author":"Kumar","year":"2022","journal-title":"J. Med. Virol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.it.2020.10.005","article-title":"Coronaviruses: innate immunity, inflammasome activation, inflammatory cell death, and cytokines","volume":"41","author":"Lee","year":"2020","journal-title":"Trends Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/13543776.2017.1378426","article-title":"Caspase inhibitors: a review of recently patented compounds (2013-2015)","volume":"28","author":"Lee","year":"2018","journal-title":"Expert Opin. Ther. patents"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1134511","article-title":"BPOZ-2 is a negative regulator of the NLPR3 inflammasome contributing to SARS-CoV-2-induced hyperinflammation","volume":"13","author":"Li","year":"2023","journal-title":"Front. Cell. infection Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-020-00334-0","article-title":"SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation","volume":"5","author":"Li","year":"2020","journal-title":"Signal transduction targeted Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature18629","article-title":"Inflammasome-activated gasdermin d causes pyroptosis by forming membrane pores","volume":"535","author":"Liu","year":"2016","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/imr.12618","article-title":"The AIM2 inflammasome: sensor of pathogens and cellular perturbations","volume":"281","author":"Lugrin","year":"2018","journal-title":"Immunol. Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/s41380-021-01431-4","article-title":"In COVID-19, NLRP3 inflammasome genetic variants are associated with critical disease and these effects are partly mediated by the sickness symptom complex: a nomothetic network approach","volume":"27","author":"Maes","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1208\/s12248-020-00532-2","article-title":"Recent developments on therapeutic and diagnostic approaches for COVID-19","volume":"23","author":"Majumder","year":"2021","journal-title":"AAPS J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00415-020-10015-1","article-title":"COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis","volume":"268","author":"Mantero","year":"2021","journal-title":"J. Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B41","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1089\/vim.2021.0071","article-title":"Interleukin-1 in COVID-19 infection: immunopathogenesis and possible therapeutic perspective","volume":"34","author":"Mardi","year":"2021","journal-title":"Viral Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/s1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202001650","article-title":"siRNA therapeutics against respiratory viral infections-what have we learned for potential COVID-19 therapies","volume":"10","author":"Mehta","year":"2021","journal-title":"Advanced healthcare materials"},{"key":"B44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/d41573-019-00086-9","article-title":"NLRP3 inhibitors stoke anti-inflammatory ambitions","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1038\/s41467-021-25015-6","article-title":"SARS-CoV-2 n protein promotes NLRP3 inflammasome activation to induce hyperinflammation","volume":"12","author":"Pan","year":"2021","journal-title":"Nat. Commun."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1038\/s41401-022-00913-7","article-title":"Novel caspase-1 inhibitor CZL80 improves neurological function in mice after progressive ischemic stroke within a long therapeutic time-window","volume":"43","author":"Pan","year":"2022","journal-title":"Acta pharmacologica Sin."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1016\/j.molcel.2022.04.033","article-title":"Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells","volume":"82","author":"Plan\u00e8s","year":"2022","journal-title":"Mol. Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.842740","article-title":"Emerging insights on caspases in COVID-19 pathogenesis, sequelae, and directed therapies","volume":"13","author":"Premeaux","year":"2022","journal-title":"Front. Immunol."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2119893119","article-title":"COVID-19 therapeutics: challenges and directions for the future","volume":"119","author":"Robinson","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay2002","article-title":"Enteroviral 3C protease activates the human NLRP1 inflammasome in airway epithelia","volume":"370","author":"Robinson","year":"2020","journal-title":"Sci. (New York N.Y.)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201707","article-title":"Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients","volume":"218","author":"Rodrigues","year":"2021","journal-title":"J. Exp. Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","article-title":"siRNA therapeutics: a clinical reality","volume":"63","author":"Saw","year":"2020","journal-title":"Sci. China. Life Sci."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.834098","article-title":"SARS-CoV-2's variants of concern: a brief characterization","volume":"13","author":"Scovino","year":"2022","journal-title":"Front. Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1146\/annurev-virology-100114-055218","article-title":"Continuous and discontinuous RNA synthesis in coronaviruses","volume":"2","author":"Sola","year":"2015","journal-title":"Annu. Rev. Virol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.1038\/ncomms9761","article-title":"Human caspase-4 and caspase-5 regulate the one-step non-canonical inflammasome activation in monocytes","volume":"6","author":"Vigan\u00f2","year":"2015","journal-title":"Nat. Commun."},{"key":"B57","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41577-021-00588-x","article-title":"Inflammasome activation at the crux of severe COVID-19","volume":"21","author":"Vora","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"Jama"},{"key":"B59","doi-asserted-by":"publisher","first-page":"9782","DOI":"10.1039\/d2fo01730j","article-title":"Sennoside a is a novel inhibitor targeting caspase-1","volume":"13","author":"Wu","year":"2022","journal-title":"Food Funct."},{"key":"B60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.virol.2022.01.003","article-title":"SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway","volume":"568","author":"Xu","year":"2022","journal-title":"Virology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4049\/jimmunol.2000513","article-title":"Inflammasomes and pyroptosis as therapeutic targets for COVID-19","volume":"205","author":"Yap","year":"2020","journal-title":"J. Immunol. (Baltimore Md. 1950)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","volume":"20","author":"Zeng","year":"2022","journal-title":"BMC Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.cytogfr.2021.06.002","article-title":"The NLRP3 inflammasome and COVID-19: activation, pathogenesis and therapeutic strategies","volume":"61","author":"Zhao","year":"2021","journal-title":"Cytokine Growth factor Rev."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1218039\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T05:10:00Z","timestamp":1686287400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1218039\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":64,"alternative-id":["10.3389\/fcimb.2023.1218039"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1218039","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"article-number":"1218039"}}